ArticleHaematologica2025
Risk of cancer in adults with primary immune thrombocytopenia: a binational population-based realworld cohort study from Denmark and France.
Article in Haematologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The association of thrombocytopenia with haematological malignancy.British journal of haematology · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune dysregulation and immunosuppression occur due to the pathophysiology and management of primary immune thrombocytopenia (ITP), which together may increase the risk of subsequent cancer. We investigated the cancer risk in ITP compared with the general population in a binational cohort study in Denmark and France. We identified 12,456 patients with ITP and 218,971 age- and sex-matched general population comparators from 1980-2018 in Danish and French health registries. All individuals were followed for solid and hematologic cancer. We estimated nation-specific five-year cumulative incidences, cause-specific [csHR], and combined meta-analysis csHR for cancer. We stratified analyses on age and sex. The five-year cumulative incidences of solid cancer in Denmark were 6.7% (95% confidence interval [CI]: 5.9-7.5) in ITP versus 6.1% (95% CI: 6.0-6.2) in comparators driven by differences in female, thorax and upper gastrointestinal cancers, and 8.4% (95% CI: 7.6-9.2) versus 6.0% (95% CI: 5.6-6.4) in France driven by skin and colorectal cancers. The corresponding numbers for hematologic cancer were 2.6% (95% CI: 2.2-3.2) versus 0.4% (95% CI: 0.4-0.5) in Denmark, and 7.6% (95% CI: 6.9-8.3) versus 1.1% (95% CI: 0.9-1.2) in France. Across both countries, differences were driven by leukemia, lymphoma, and other hematologic cancers. The five-year adjusted csHR for solid cancer were 1.3 (95% CI: 1.1-1.5) in Denmark, 1.3 (95% CI: 1.2-1.5) in France, and 1.3 (95% CI: 1.2-1.4) combined. CsHR for hematologic cancer were 7.4 (95% CI: 6.1-9.1) in Denmark, 9.0 (95% CI: 7.5-10.8) in France, and 8.2 (95% CI: 6.8-9.9) combined. Risks were highest during the first year after ITP diagnosis, and in younger and female patients. The risk of cancer following ITP increased, with risk of hematologic cancer in particular. This knowledge should influence treatment and follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.